| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22009 |
| Drug | Avacopan |
| Brand | Tavneos® |
| Indication | In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic polyangiitis. |
| Assessment Process | |
| Rapid review commissioned | 14/02/2022 |
| Rapid review completed | 08/03/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avacopan (Tavneos®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/04/2022 |
| Pre-submission consultation with Applicant | 21/06/2022 |
| Full submission received from Applicant | 19/10/2022 |
| Preliminary review sent to Applicant | 24/02/2023 |
| NCPE assessment re-commenced | 28/04/2023 |
| Factual accuracy sent to Applicant | 03/07/2023 |
| NCPE assessment re-commenced | 11/07/2023 |
| NCPE assessment completed | 20/07/2023 |
| NCPE assessment outcome | The NCPE recommends that avacopan not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
